Difference between revisions of "Workshop on Clinical Trial Ontology"
| Line 5: | Line 5: | ||
== Aim of the workshop == | == Aim of the workshop == | ||
| − | The aim of the workshop is to foster the creation of a reference ontology (high-quality controlled structured vocabulary) for clinical trial annotation. The ontology should comprehend terms like: ''cohort, randomization, placebo, response, efficacy, control, protocol, null hypothesis, confidence interval, finding, biomarker, primary outcome, secondary outcome, intervention group, experimental design, '' etc., including also major relevant statistical terms and terms drawn from the CDISC [http://www.cdisc.org/glossary/clinicalterminologyv4.pdf glossary.]The ontology will organize these terms in a structured way, providing definitions and logical relations designed to advance reasoning with the data annotated in its terms. | + | The aim of the workshop is to foster the creation of a reference ontology (high-quality controlled structured vocabulary) for clinical trial annotation. The ontology should comprehend terms like: ''cohort, randomization, placebo, response, efficacy, control, protocol, null hypothesis, confidence interval, finding, biomarker, primary outcome, secondary outcome, intervention group, experimental design, '' etc., including also major relevant statistical terms and terms drawn from resources such as the CDISC [http://www.cdisc.org/glossary/clinicalterminologyv4.pdf glossary.] The ontology will organize these terms in a structured way, providing definitions and logical relations designed to advance reasoning with the data annotated in its terms. |
The proposed CTO should: | The proposed CTO should: | ||
Revision as of 09:46, 28 November 2006
General Information
The National Center for Biomedical Ontology will host a two-day workshop focused on the Ontology of Clinical Trials. The workshop will take place in May 16-17, 2007 at a venue to be determined.
Aim of the workshop
The aim of the workshop is to foster the creation of a reference ontology (high-quality controlled structured vocabulary) for clinical trial annotation. The ontology should comprehend terms like: cohort, randomization, placebo, response, efficacy, control, protocol, null hypothesis, confidence interval, finding, biomarker, primary outcome, secondary outcome, intervention group, experimental design, etc., including also major relevant statistical terms and terms drawn from resources such as the CDISC glossary. The ontology will organize these terms in a structured way, providing definitions and logical relations designed to advance reasoning with the data annotated in its terms.
The proposed CTO should:
(1) fully and faithfully capture the types of entities and relationships involved in clinical trials of any experimental design
(2) comprehend all the terms needed for the task of meta-analysis of clinical trials
(3) support trial bank interoperation
(4) form an integral part of a more comprehensive investigation ontology, including also the Ontology for Biomedical Investigations OBI, which forms part of the OBO Foundry, and drawing on the Epoch ontology used by the Immune Tolerance Network.
The purpose of the meeting is to bring together representatives of the major groups involved in clinical trial informatics, design, execution, analysis and standardization in order to approve an initial draft of the CTO and create a strategy for its further development and testing.
Further topics to be addressed include:
i. The relation between CTO and data-model-oriented initiatives (HL7, CDISC, BRIDG, caBIG).
ii. The relation between CTO and a drug (trial) ontology
iii. The relation between CTO and an epidemiology study ontology
iv. The proper treatment of types (surgical intervention, tumor, human being) and instances (Jane's oophorectomy, John's tumor, Fritz) in ontologies and related artifacts.
v. The relation between CTO, Trialbank, and OBD.
Agenda
Participation
PLEASE NOTE THAT PARTICIPATION IN THIS MEETING IS RESTRICTED.
If you wish to be considered for participation, please send a brief statement to Barry Smith.
Participants (Provisional List)
All participants will be required to register. Registration details will be available in due course.
Carol Bean -- NIH/NHLBI
Werner Ceusters -- NCBO, University at Buffalo
Chris Chute -- NCBO, Mayo Clinic, Rochester, MN
Lindsay Cowell -- Duke University
Liju Fan -- Ontology Workshop, LLC
Kerstin Forsberg -- AstraZeneca
Jennifer Fostel -- NIH/NIEHS
Gilberto Fragoso -- NIH/NCI
Douglas Fridsma -- University of Pittsburgh
Louis J. Goldberg -- University at Buffalo
Federico Goodsaid -- (FDA CDER, Office of Clinical Pharmacology)
Norbert Graf -- ACGT, Homburg, Germany
Ted Grasela -- Cognigen Corporation, Amherst, NY
Steve Harris -- Computing Laboratory, University of Oxford
Tina Hernandez-Boussard -- PharmGKB, Stanford University
Randy Levin -- CDER
Suzanna Lewis -- NCBO, Berkeley, CA
Peter Maccallum -- UK CancerGrid, Department of Oncology, University of Cambridge
Chris Mungall -- Howard Hughes Institute, Berkeley, CA
Mark Musen -- NCBO, Stanford University, CA
Fabian Neuhaus -– NCBO, University at Buffalo, NY
Dave Parrish -- Immune Tolerance Network, Pittsburgh, PA
Philippe Rocca-Serra -- EBI, Hinxton, Cambridge
Nigam Shah -– NCBO, Stanford Medical Informatics
Susanna Sansone -- EBI, Hinxton, Cambridge
Ida Sim -- NCBO, University of California at San Francisco Medical Center
Barry Smith -– NCBO, University at Buffalo
Holger Stenzhorn -- IFOMIS, Saarbrücken
Weida Tong -- Center for Toxicoinformatics, FDA NCTR
Trish Whetzel -- University of Pennsylvania
Samson Tu -- Stanford University
Gabriele Weiler -- Fraunhofer Institute, Sankt Ingbert, Germany
Chunhua Weng -- University of Pittsburgh